Phaseline

Targets › PTK2

PTK2 (Focal adhesion kinase 1): drug programs, companies and trials

4 programs from 4 companies in 32 trials: 15 Phase 2, 15 Phase 1, 2 Phase 3; Oncology; next expected readout Dec 2026.

Non-receptor protein-tyrosine kinase that plays an essential role in regulating cell migration, adhesion, spreading, reorganization of the actin cytoskeleton, formation and disassembly of focal adhesions and cell protrusions, cell cycle progression, cell proliferation and apoptosis. Required for early embryonic development and placenta development. (UniProt, Q05397)

Open in Phaseline: the race on PTK2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Verastemdefactinib
Focal adhesion kinase 1 inhibitor; Protein tyrosine kinase 2 beta inhibitor
PTK2, PTK2BPhase 3Low Grade Serous Ovarian Cancer; Low Grade Ovarian Serous Adenocarcinoma; Non Small Cell Lung Cancer; KRAS Activating Mutation …Dec 2026
InxMed (Shanghai)Ifebemtinib (IN10018)
Focal adhesion kinase 1 inhibitor
PTK2Phase 3Non-Small Cell Lung Cancer; Ovarian Cancer Recurrent; Small Cell Lung Cancer Extensive Stage; Pancreatic Cancer …Dec 2026
Alliance for Clinical Trials in OncologyFAK Inhibitor GSK2256098
Focal adhesion kinase (FAK) inhibitor
PTK2Phase 2Intracranial MeningiomaJun 2028
Amplia TherapeuticsAMP945
focal adhesion kinase (FAK) inhibitor
PTK2Phase 1Pancreatic CancerFeb 2027

Conditions

Pancreatic Cancer (2) NSCLC (2) Low Grade Serous Ovarian Cancer (2) Non-Small Cell Lung Cancer (1) Ovarian Cancer Recurrent (1) Small Cell Lung Cancer Extensive Stage (1) Platinum-resistant Ovarian Cancer (1) Solid Tumor (1) Solid Tumor Cancer (1) Cervical Adenocarcinoma (1) Meningioma (1) Intracranial Meningioma (1)

Modalities

small molecule (4)

Companies

InxMed (Shanghai) (1) Alliance for Clinical Trials in Oncology (1) Verastem (1) Amplia Therapeutics (1)

Related targets

PTK2B (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.